Story
Air Products Sentiment Turns Bullish on 'Beat and Raise' Hopes, BofA Says

Summary
Investor sentiment for Air Products and Chemicals has turned positive following a major project cancellation, with clients of Bank of America now expecting the company to beat Q3 estimates and raise its full-year guidance.
Investor sentiment surrounding Air Products and Chemicals (NYSE: APD) has turned decidedly bullish, with market participants anticipating the company will beat fiscal third-quarter estimates and raise its full-year guidance, according to a new Bank of America client note. The shift in outlook follows the company's formal cancellation of its Darrow, Louisiana, blue hydrogen project.
Bullish Outlook for Air Products
Bank of America's report indicates that clients are optimistic about Air Products' upcoming earnings report, citing several potential drivers. Investors expect strength to come from a combination of cost reductions, improved pricing power, and rising helium prices.
Following strong earnings beats in the first two fiscal quarters, discussions among investors now point to a potential new earnings per share (EPS) guidance range of $13.15 to $13.35 for fiscal 2026, the note stated.
Expectations Across the Chemical Sector
AdBank of America's note also provided a snapshot of investor sentiment for several other major chemical companies ahead of their earnings reports, revealing a mixed but generally positive set of expectations.
- Linde (NYSE: LIN): Expected to raise full-year guidance to 8% to 10% EPS growth, implying a new range of $17.75 to $18.10 per share.
- Dow (NYSE: DOW): Anticipated to report second-quarter EBITDA above its $2.2 billion guidance, although clients expect a softer Q3 outlook.
- Ecolab (NYSE: ECL): Investors widely expect the company to beat Q2 estimates and raise its full-year earnings guidance, viewing its July 2 update as conservative.
- PPG Industries (NYSE: PPG): The consensus is for a Q2 earnings beat of more than $0.04 per share and a reiteration of 2026 guidance, with a possible increase at the low end.
- Mosaic (NYSE: MOS): In contrast, results are expected to be soft for the second quarter. The note highlighted concerns about the company's outlook due to volume pressures and fixed cost absorption from idled capacity.
Market Context
This type of pre-earnings channel check provides institutional investors with a glimpse into the prevailing sentiment on Wall Street. For the chemicals sector, the expectations suggest a varied operating environment where company-specific actions, such as cost-cutting and project management, are key differentiators. While some firms are poised to benefit from pricing power and efficiency gains, others face headwinds from capacity and volume challenges.
Read next
More on Stocks
AutoZone Shares Jump as Strong Margins Outweigh Revenue Miss
The auto parts retailer reported fiscal fourth-quarter earnings that surpassed analyst expectations, driven by significant margin expansion, even as revenue fell short of forecasts for the fourth consecutive quarter.

Anthropic Launches Cheaper, Faster Claude 5.5 AI Model Ahead of Potential IPO
Anthropic has released its new flagship AI model, Claude Opus 5.5, which the company says is 40% cheaper and over 30% faster for enterprise use. The launch intensifies competition in the AI sector as the startup reportedly prepares for an initial public offering.

Bank of America Lifts Cybersecurity Price Targets on AI Threat Concerns
Bank of America has raised its price objectives for CrowdStrike, Okta, and SailPoint, citing growing investor recognition that artificial intelligence creates new security risks requiring significant investment. The cybersecurity sector has recently outperformed the broader market as the focus shifts to AI governance and threat mitigation.

AnaptysBio Stock Drops Despite Massive Q2 Earnings Beat as GSK Court Ruling Looms
AnaptysBio reported a significant earnings and revenue surprise for the second quarter, driven by strong Jemperli royalties. However, shares fell as investor attention remains fixed on the pending outcome of a key court case with partner GSK.